MOUNTAIN VIEW, Calif., Aug. 9, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the following investor conferences:
Canaccord Genuity 32nd Annual Growth Conference
Thursday, August 16, at 11:30 a.m. ET in Boston
Stifel Nicolaus Annual Healthcare Conference
Thursday, September 6, at 8:00 a.m. ET in Boston
A live webcast of each presentation will be available on the Investor Relations section of MAP Pharmaceuticals’ website at http://www.mappharma.com. A replay also will be available within 24 hours for seven days following each presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The U.S. Food and Drug Administration (FDA) reviewed the New Drug Application (NDA) for LEVADEX and on March 26, 2012, the Company received a Complete Response letter with respect to this NDA. The Company completed an End-of-Review meeting with the FDA and plans to resubmit in the late third quarter/early fourth quarter 2012 timeframe. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
CONTACT:
Lisa Borland
MAP Pharmaceuticals, Inc.
650-386-3122
lborland@mappharma.com
SOURCE MAP Pharmaceuticals, Inc.
